Naxitamab is humanized monoclonal antibody that targets GD2 antigen.
GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including tumors such as neuroblastoma, melanoma and osteosarcoma.
Naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system by binding to the GD2 antigen on the surface of the tumor, thereby achieving the effect of killing the tumor.
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
